Aclarion (ACON) Competitors

$3.22 -0.06 (-1.83%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$3.18 -0.04 (-1.09%)

As of 04:40 AM Eastern

ACON vs. CCM, PIII, BMGL, ADVB, and MRAI

Should you buy Aclarion stock or one of its competitors? MarketBeat compares Aclarion with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aclarion include Concord Medical Services (CCM), P3 Health Partners (PIII), Basel Medical Group (BMGL), Advanced Biomed (ADVB), and Marpai (MRAI). These companies are all part of the "healthcare" industry.

How does Aclarion compare to Concord Medical Services?

Aclarion (NASDAQ:ACON) and Concord Medical Services (NYSE:CCM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

7.5% of Aclarion shares are held by institutional investors. 0.8% of Aclarion shares are held by company insiders. Comparatively, 46.5% of Concord Medical Services shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Aclarion had 8 more articles in the media than Concord Medical Services. MarketBeat recorded 9 mentions for Aclarion and 1 mentions for Concord Medical Services. Aclarion's average media sentiment score of 1.05 beat Concord Medical Services' score of 0.75 indicating that Aclarion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclarion	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Concord Medical Services	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Concord Medical Services	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aclarion has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Concord Medical Services has a beta of -1.09, meaning that its stock price is 209% less volatile than the broader market.

Aclarion has higher earnings, but lower revenue than Concord Medical Services.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	99.02	-$7.23M	-$17.01	N/A
Concord Medical Services	$65.85M	0.33	-$13.27M	N/A	N/A

Concord Medical Services has a net margin of 0.00% compared to Aclarion's net margin of -10,320.51%. Concord Medical Services' return on equity of 0.00% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-61.10%	-58.01%
Concord Medical Services	N/A	N/A	N/A

Summary

Aclarion beats Concord Medical Services on 6 of the 11 factors compared between the two stocks.

How does Aclarion compare to P3 Health Partners?

Aclarion (NASDAQ:ACON) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

In the previous week, Aclarion had 5 more articles in the media than P3 Health Partners. MarketBeat recorded 9 mentions for Aclarion and 4 mentions for P3 Health Partners. Aclarion's average media sentiment score of 1.05 beat P3 Health Partners' score of 0.93 indicating that Aclarion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclarion	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
P3 Health Partners	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

P3 Health Partners has a consensus target price of $3.50, suggesting a potential downside of 13.15%. Given P3 Health Partners' stronger consensus rating and higher probable upside, analysts clearly believe P3 Health Partners is more favorable than Aclarion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aclarion has higher earnings, but lower revenue than P3 Health Partners. Aclarion is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	99.02	-$7.23M	-$17.01	N/A
P3 Health Partners	$1.46B	0.02	-$147.95M	-$45.20	N/A

P3 Health Partners has a net margin of -10.14% compared to Aclarion's net margin of -10,320.51%. Aclarion's return on equity of -61.10% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-61.10%	-58.01%
P3 Health Partners	-10.14%	-302.33%	-20.72%

Aclarion has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, P3 Health Partners has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market.

7.5% of Aclarion shares are held by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are held by institutional investors. 0.8% of Aclarion shares are held by company insiders. Comparatively, 17.8% of P3 Health Partners shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

P3 Health Partners beats Aclarion on 9 of the 16 factors compared between the two stocks.

How does Aclarion compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

In the previous week, Aclarion had 7 more articles in the media than Basel Medical Group. MarketBeat recorded 9 mentions for Aclarion and 2 mentions for Basel Medical Group. Basel Medical Group's average media sentiment score of 1.31 beat Aclarion's score of 1.05 indicating that Basel Medical Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Basel Medical Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclarion	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aclarion has lower revenue, but higher earnings than Basel Medical Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90M	1.48	-$9.50M	N/A	N/A
Aclarion	$80K	99.02	-$7.23M	-$17.01	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

7.5% of Aclarion shares are owned by institutional investors. 0.8% of Aclarion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Basel Medical Group has a net margin of 0.00% compared to Aclarion's net margin of -10,320.51%. Basel Medical Group's return on equity of 0.00% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
Aclarion	-10,320.51%	-61.10%	-58.01%

Basel Medical Group has a beta of 0.07, indicating that its stock price is 93% less volatile than the broader market. Comparatively, Aclarion has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

Summary

Aclarion beats Basel Medical Group on 6 of the 11 factors compared between the two stocks.

How does Aclarion compare to Advanced Biomed?

Advanced Biomed (NASDAQ:ADVB) and Aclarion (NASDAQ:ACON) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Biomed	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Advanced Biomed has a net margin of 0.00% compared to Aclarion's net margin of -10,320.51%. Advanced Biomed's return on equity of 92.11% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Advanced Biomed	N/A	92.11%	58.03%
Aclarion	-10,320.51%	-61.10%	-58.01%

7.5% of Aclarion shares are owned by institutional investors. 34.4% of Advanced Biomed shares are owned by insiders. Comparatively, 0.8% of Aclarion shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Aclarion had 7 more articles in the media than Advanced Biomed. MarketBeat recorded 9 mentions for Aclarion and 2 mentions for Advanced Biomed. Advanced Biomed's average media sentiment score of 1.21 beat Aclarion's score of 1.05 indicating that Advanced Biomed is being referred to more favorably in the media.

Company	Overall Sentiment
Advanced Biomed	Positive
Aclarion	Positive

Advanced Biomed has higher earnings, but lower revenue than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Biomed	N/A	N/A	-$3.26M	$3.80	1.17
Aclarion	$80K	99.02	-$7.23M	-$17.01	N/A

Advanced Biomed has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Aclarion has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Summary

Advanced Biomed beats Aclarion on 8 of the 12 factors compared between the two stocks.

How does Aclarion compare to Marpai?

Aclarion (NASDAQ:ACON) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Marpai has a net margin of -85.70% compared to Aclarion's net margin of -10,320.51%. Marpai's return on equity of 0.00% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,320.51%	-61.10%	-58.01%
Marpai	-85.70%	N/A	-100.23%

7.5% of Aclarion shares are owned by institutional investors. Comparatively, 49.8% of Marpai shares are owned by institutional investors. 0.8% of Aclarion shares are owned by company insiders. Comparatively, 46.1% of Marpai shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Aclarion had 7 more articles in the media than Marpai. MarketBeat recorded 9 mentions for Aclarion and 2 mentions for Marpai. Aclarion's average media sentiment score of 1.05 beat Marpai's score of 0.00 indicating that Aclarion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclarion	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Marpai	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aclarion has higher earnings, but lower revenue than Marpai. Marpai is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	99.02	-$7.23M	-$17.01	N/A
Marpai	$34.87M	0.22	-$28.75M	-$0.95	N/A

Aclarion has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Marpai has a beta of 4.38, suggesting that its share price is 338% more volatile than the broader market.

Summary

Marpai beats Aclarion on 8 of the 14 factors compared between the two stocks.

Get Aclarion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACON vs. The Competition

Export

Metric	Aclarion	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.08M	$8.35B	$6.34B	$12.37B
Dividend Yield	N/A	3.03%	2.80%	5.35%
P/E Ratio	-0.36	21.76	20.66	25.63
Price / Sales	99.02	16.95	547.02	76.59
Price / Cash	N/A	81.29	43.26	56.33
Price / Book	0.21	5.65	9.93	6.97
Net Income	-$7.23M	$183.43M	$3.55B	$333.62M
7 Day Performance	1.26%	0.26%	1.69%	1.09%
1 Month Performance	0.63%	10.62%	0.48%	3.08%
1 Year Performance	-53.33%	3.60%	39.38%	35.68%

Aclarion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACON Aclarion	1.2198 of 5 stars	$3.22 -1.8%	N/A	-55.0%	$8.08M	$80K	N/A	7	Positive News Earnings Report Upcoming Earnings
CCM Concord Medical Services	0.7305 of 5 stars	$4.74 -3.4%	N/A	-38.4%	$21.27M	$65.85M	N/A	970	High Trading Volume
PIII P3 Health Partners	1.0808 of 5 stars	$2.89 +1.4%	$3.50 +21.1%	-50.7%	$20.56M	$1.46B	N/A	500	News Coverage Gap Up
BMGL Basel Medical Group	0.5874 of 5 stars	$0.61 +5.0%	N/A	-63.2%	$10.86M	$8.90M	N/A	36	Gap Down
ADVB Advanced Biomed	1.2577 of 5 stars	$6.86 +15.1%	N/A	N/A	$8.13M	N/A	1.81	40	Positive News Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACON) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aclarion (ACON) Competitors

ACON vs. CCM, PIII, BMGL, ADVB, and MRAI

How does Aclarion compare to Concord Medical Services?

Summary

How does Aclarion compare to P3 Health Partners?

Summary

How does Aclarion compare to Basel Medical Group?

Summary

How does Aclarion compare to Advanced Biomed?

Summary

How does Aclarion compare to Marpai?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACON vs. The Competition

Aclarion Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aclarion (ACON) Competitors

ACON vs. CCM, PIII, BMGL, ADVB, and MRAI

How does Aclarion compare to Concord Medical Services?

Do institutionals & insiders hold more shares of ACON or CCM?

Does the media prefer ACON or CCM?

Do analysts rate ACON or CCM?

Which has more risk & volatility, ACON or CCM?

Which has higher earnings & valuation, ACON or CCM?

Is ACON or CCM more profitable?

Summary

How does Aclarion compare to P3 Health Partners?

Does the media refer more to ACON or PIII?

Do analysts recommend ACON or PIII?

Which has stronger valuation & earnings, ACON or PIII?

Is ACON or PIII more profitable?

Which has more volatility & risk, ACON or PIII?

Do insiders and institutionals have more ownership in ACON or PIII?

Summary

How does Aclarion compare to Basel Medical Group?

Does the media prefer BMGL or ACON?

Which has stronger valuation & earnings, BMGL or ACON?

Do analysts rate BMGL or ACON?

Do insiders & institutionals hold more shares of BMGL or ACON?

Is BMGL or ACON more profitable?

Which has more volatility & risk, BMGL or ACON?

Summary

How does Aclarion compare to Advanced Biomed?

Do analysts recommend ADVB or ACON?

Is ADVB or ACON more profitable?

Do institutionals & insiders hold more shares of ADVB or ACON?

Does the media favor ADVB or ACON?

Which has stronger earnings and valuation, ADVB or ACON?

Which has more volatility and risk, ADVB or ACON?

Summary

How does Aclarion compare to Marpai?

Do analysts recommend ACON or MRAI?

Is ACON or MRAI more profitable?

Do insiders and institutionals hold more shares of ACON or MRAI?

Does the media refer more to ACON or MRAI?

Which has higher earnings & valuation, ACON or MRAI?

Which has more risk and volatility, ACON or MRAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACON vs. The Competition

Aclarion Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools